<DOC>
	<DOCNO>NCT02119884</DOCNO>
	<brief_summary>The purpose study find patient 's response terlipressin octreotide hepatic venous pressure gradient measurement observe portal systemic hemodynamics .</brief_summary>
	<brief_title>Hemodynamic Effects Terlipressin High Dose Octreotide</brief_title>
	<detailed_description>Esophageal variceal bleed one main cause death cirrhosis patient . Prevention bleed event , include primary secondary prophylaxis , important reduce mortality variceal bleeding . Terlipressin octreotide effectively control bleed side effect , recommend Baveno V treatment acute variceal bleeding . Terlipressin high dose octreotide administered patient cirrhosis relate esophageal varix undergo hepatic venous pressure gradient measurement . Changes portal systemic hemodynamics observe evaluate safety effect terlipressin high dose octreotide well determine wether patient respond . The result serve clinical evidence prevent re-bleeding long-acting terlipressin octreotide future .</detailed_description>
	<mesh_term>Esophageal Gastric Varices</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<mesh_term>Terlipressin</mesh_term>
	<mesh_term>Lypressin</mesh_term>
	<criteria>Gastric Esophageal Varices confirm endoscopy Liver Biopsy , CT MRI indicate cirrhosis Patients experience variceal bleed The patient beyond range 18 80 year old The patient unstable vital sign The patient spontaneous peritonitis severe infection The patient hepatorenal syndrome renal inadequacy The patient uncontrolled hepatic encephalopathy Pregnant lactate woman The patient contraindication terlipressin octreotide The patient refuse take part study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Gastric Esophageal Varices</keyword>
	<keyword>Hepatic Venous Pressure Gradient</keyword>
	<keyword>Terlipressin</keyword>
	<keyword>Octreotide</keyword>
</DOC>